A possible mechanism of the antagonistic action of oxaliplatin in combination with anti-EGFR could be the fibroblast rich tumour microenvironment of CMS4 cancers, that increases the effects of oxaliplatin induced cytokines, which might subsequently antagonise the antitumor effects of cetuximab and the cetuximab-oxaliplatin synergy [16]. This evidence concerns the gene EGFR and cancer.